Akoya Biosciences

Phase A — Understand the business

Lens 1 · Company Overview

Plain-terms model. Akoya Biosciences was "The Spatial Biology Company" — a life-science tools vendor selling instruments and the consumables that run on them, on a razor / razor-blade model. Customers (academic labs, cancer centers, pharma/biotech R&D, CROs) buy a benchtop imaging instrument once, then buy antibody-reagent panels and kits to run every experiment. The science: spatial proteomics — mapping where 100+ protein markers sit, cell-by-cell, across an intact tissue slide (including archival FFPE blocks), so a researcher can see how cells organize and interact rather than averaging them in a blender.

Key products. Two platform families, fused into one workflow:

• PhenoCycler (originally CODEX, acquired via the Canopy Biosciences buy in 2020): an automated, ultra-high-plex cycling chemistry — antibodies tagged with oligonucleotide barcodes, applied in sequential cycles to image 100+ markers at single-cell / sub-cellular resolution.
• PhenoImager (originally Phenoptics, the portfolio Akoya carved out of PerkinElmer at founding): high-speed multispectral imaging; the PhenoImager HT is the higher-throughput, clinical-translational end (300+ samples/week).
• PhenoCycler-Fusion (commercial launch Jan 2022; "2.0" refresh later): the integrated instrument that fuses cycling + imaging into one end-to-end system — Akoya's flagship and the "fastest single-cell spatial biology system" claim.
• PhenoCode panels / reagents: the recurring-revenue consumables layer.

Customers / suppliers / competitors. Customers were overwhelmingly research-grade (academic + pharma/translational), with a stated ambition to push into clinical/diagnostic use — the higher-value, recurring, regulated end Akoya never fully reached as a standalone. customers.csv is empty in the research layer (n/a for named-account concentration). Suppliers: antibody / reagent vendors and instrument contract manufacturers (not disclosed at name level here — n/a). Competitors: 10x Genomics (Xenium / Visium / the new Atera), Bruker (which absorbed bankrupt NanoString's GeoMx + CosMx), Vizgen (merged with Ultivue), Standard BioTools, RareCyte, Lunaphore (Bio-Techne).

Contract structure / payment terms. Instrument sales = lumpy, upfront capital equipment (no take-or-pay, no multi-year lock-in). Consumables = recurring but only as long as the installed base runs experiments — i.e. demand is gated by the customer's grant funding, not contracted. This is the structural weakness that the 2025 funding winter exposed (see Lens 5, 13).

History in one line. Founded 2015 (Phenoptics carve-out from PerkinElmer); roll-up of spatial assets (Canopy/CODEX 2020, Acuity Spatial Genomics 2021); IPO April 2021 at $20.00/share, ~$151M raised, peak market cap ~$714M; serial revenue misses + cash burn 2023-2024; acquired by Quanterix and delisted July 2025 at $1.29 (−91% from IPO).

Lens 2 · Supply Chain

Map: antibody & oligo-reagent suppliers → Akoya (panel + kit manufacturing, instrument assembly via CM) → instrument + consumables → end lab (academic / pharma / CRO) → (aspirationally) clinical diagnostics.

Named stakeholders that are sourceable:

• Upstream / heritage: PerkinElmer (source of the Phenoptics imaging IP), Canopy Biosciences (CODEX chemistry), Acuity Spatial Genomics (spatial-genomics tuck-in).
• Partner (commercial/menu expansion): Thermo Fisher Scientific — Akoya partnered with Thermo for combined RNA + protein analysis, an attempt to widen the menu against 10x's multi-omic push.
• Downstream buyer (the new parent): Quanterix — now the owner; the integration thesis is to cross-sell Akoya tissue instruments into Quanterix's Simoa blood-biomarker installed base and vice-versa (combined ~2,300 instruments).

Chokepoints / single-source dependencies: the genuine chokepoint is antibody-conjugate quality and panel validation — the consumable is the moat and the cost center; reagent supply and QC are the single most important operational dependency. Specific supplier names are n/a (no supply-chain.md in the commercial layer; customers.csv/capex-detail.csv empty). This lens is thinner than the skill's "names or it didn't happen" bar precisely because the company is delisted and the research layer was never deep-ingested — flagged, not faked.

Lens 3 · Competitive Advantages (moats)

What was genuinely defensible:

1. High-plex on FFPE + single-system tunability. PhenoCycler-Fusion let one instrument run both discovery (large, hypothesis-free panels) and validation (focused panels), then translate signatures onto the PhenoImager HT for higher throughput — a workflow continuity competitors had to stitch from multiple boxes. Real, but a feature moat, not a structural one.
2. Installed-base lock-in (razor/razorblade). ~1,264 instruments by Q2-2024 (374 PhenoCyclers, 890 PhenoImagers), +18.8% YoY; consumables = ~53% of product revenue in FY2024. Each placed box is a recurring-reagent annuity — the asset Quanterix paid for.
3. CODEX brand + published-method base in academic spatial-proteomics literature (switching cost = retraining + re-validating panels).

Why the moat was thin in practice:

• No contractual lock-in and funding-gated pull-through — consumable revenue evaporates when grants dry up, so the "annuity" is soft (see Lens 5/13).
• Bargaining power was weak on both sides: customers are price-sensitive academics with collapsing budgets; the most dangerous competitor (10x Genomics) is far larger, better-capitalized, and pushing into spatial proteomics (it acquired proteomics capability and launched Atera) — squeezing Akoya from above.
• Sub-scale. At ~$82M revenue and persistent losses, Akoya lacked the balance sheet to out-spend 10x or out-last a downturn. A moat you cannot afford to defend is not a moat. The delisting price ($1.29) is the market's verdict on the durability of this moat.

Lens 4 · Segments

Akoya did not report multiple operating segments; the meaningful cut is revenue by type (instruments vs. consumables vs. services) and the trend. segments.csv is empty (n/a at the research-layer level); the figures below are `` from FY2024 results.

• Total revenue: FY2021 $54.9M → … → FY2023 ~$96M → FY2024 $81.7M (−15% YoY), with FY2024 guidance of $114–118M cut hard mid-year and ultimately missed by ~$33M+ vs. the high end.
• Geography: US-weighted (academic/translational), with international research markets; precise geographic split n/a.
• Read-through: the segment story is the thesis-breaker — a tools company whose instrument line (the customer-acquisition engine that seeds future consumables) goes into reverse is structurally impaired, because it stops growing the razor base that the razor-blade annuity depends on.

---

Phase B — Measure performance

Lens 5 · Earnings Result (the trajectory into the close)

Akoya's last full standalone results paint a company cutting its way toward a cash cliff it could not reach in time.

FY2024 (final full year as a standalone):

• Revenue $81.7M, −15% YoY (driven by the instrument decline).
• Gross profit $47.9M; gross margin ~58.6% (up ~1pt YoY on mix + efficiency).
• Loss from operations $(46.7)M (improved from $(57.7)M — cost-cutting working on the expense line).
• Net loss $(55.4)M (improved from $(63.3)M); EPS $(1.12) vs $(1.43).
• Cash, equivalents & marketable securities $35.0M at 31-Dec-2024.

Q1 2025 (final reported quarter before close):

• Revenue $16.6M, −9.8% YoY ($18.4M PY).
• Gross margin 59.3% vs 45.7% PY — a genuinely large, real improvement (mix toward consumables + cost actions).
• Operating expenses $23.3M (−22.3% YoY); operating loss $(13.4)M (improved from $(21.6)M).
• Cash $27.5M at 31-Mar-2025 — down ~$7.5M in one quarter despite a much-reduced burn ($7.2M operating-cash use vs. $20.8M PY).

The flag. Run the arithmetic: $27.5M of cash against a quarterly operating burn that, even after a 65% reduction, was still ~$7M. That is a company with ~1 year of life and a declining top line in a sector where capital froze. The improving margins and shrinking losses are real and to management's credit — but they were racing a clock, and the merger is what stopped the clock. Market reaction over the period: the stock traded down to penny-stock levels (~$1.29 at the last trade) — the market had fully priced terminal risk well before the deal closed.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts in the research layer (transcripts=0); this is a ``-reconstructed read of the 2023→2025 call arc.

• 2023: confident "spatial biology is going mainstream / clinical translation is coming" framing; growth-story tone.
• Mid-2024 (Q2/Q3): tone breaks. Management repeatedly cites "capital-equipment purchase constraints across the life-science tools market," slashes FY2024 guidance, and pivots the narrative from growth to "path to cash-flow positivity" and cost discipline. Q3-2024 revenue −25% to $18.8M was the gut-punch print.
• 2025: the language is survival + strategic-alternatives; by Q1-2025 every release carries the "pending acquisition by Quanterix" banner. The independent-company narrative is effectively over.

Recurring phrases that appeared: "spatial phenotyping," "installed base," "consumables pull-through," "path to profitability/cash-flow positive." Phrases that disappeared: the bullish multi-year revenue-growth and clinical-diagnostics-ramp language from 2021-2023. The sentiment trajectory is a textbook growth-story-to-going-concern arc — and it is the single clearest qualitative signal that the standalone equity was impaired.

Lens 7 · Comps

The only honest comp statement: the sector de-rated hard — spatial-biology top-5 revenue growth slumped from +21% to +9% YoY (Jan-2024→Jun-2025 window) and academically-exposed names (10x −19%, Bruker −14%, Illumina −10.8%, Agilent −11% in the March-2025 NIH-cut selloff) all fell. Akoya's ~0.8× EV/sales terminal valuation is what a sub-scale, cash-burning tools company is worth when the marginal buyer of its instruments has had its grant cancelled. Precise live peer multiples are not sourced here — flag, don't fabricate.

Lens 8 · Stock-Price Catalysts (the >5% movers, 2021→delist)

The pattern is unusually clean and one-directional:

• Apr 2021 — IPO at $20.00, ~$714M peak cap. The high-water mark.
• 2022-2023 — serial de-rating on the broad life-tools/SPAC-era growth-stock unwind + rising rates (long-duration, profitless growth punished).
• Mid-2024 — guidance cut(s). The Q3-2024 −25% revenue print + FY guide slash were the decisive fundamental catalysts; the stock entered penny territory.
• 14-Nov-2024 — "unaffected" price that the original Quanterix offer was struck against (the 0.318 all-stock ratio = a stated 19% premium to this level — i.e. the unaffected price was already deeply depressed).
• 10-Jan-2025 — Quanterix all-stock deal announced (~$286M, 0.318 ratio).
• 28-Apr-2025 — deal AMENDED DOWN to 0.1461 QTRX + $0.38 cash (Akoya owners cut from ~30%→~16% of combined co). A renegotiation against the seller is itself a negative catalyst/tell.
• 7-Jul-2025 — last trade $1.29; 8-Jul-2025 — delisted.

What the market actually reacted to: (1) revenue/guidance (every miss was punished), (2) the macro funding regime (rates, then NIH cuts), and (3) deal terms. There was no single-customer or product-launch catalyst that ever re-rated it up durably — the launches (PhenoCycler-Fusion 2.0) did not move the fundamentals enough to matter. Lesson: this was a macro-and-execution-driven name, not a story-driven one.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO — Brian McKelligon (CEO since ~2017, founding-era). Background: VP Sales & Support at 10x Genomics, business development at Cellular Dynamics International, and Ion Torrent (acquired by Life Technologies). A genuine spatial/genomics-tools commercial operator.
• Track record: built the company — carved Phenoptics out of PerkinElmer, rolled up CODEX (Canopy) and Acuity, launched PhenoCycler-Fusion, took it public at $20. That is real platform-building. But he also presided over the round-trip from $20 to $1.29, three+ years of losses, and a revenue line that peaked and rolled over. The honest verdict: a strong product/commercial founder who could not solve the capital-intensity-vs-funding problem — and, to his credit, sold the company rather than diluting shareholders into oblivion.
• Capital allocation: acquisitive (Canopy, Acuity) on the way up; the defining capital-allocation decision was selling to Quanterix at a depressed price — defensible as the least-bad option for a sub-scale tools co facing a funding winter with ~1yr of cash.
• Skin in the game / insider ownership: n/a (no insider-transactions.csv).
• Archetype: founder/commercial-builder, not a turnaround-CFO type. Appropriate for the growth phase; the company needed the latter for the down-cycle.
• Red flags on management: none of the promotional/related-party variety surfaced in search. The "red flag" here is strategic, not ethical — repeated guidance misses (a credibility cost) and the decision to IPO a capital-intensive tools business that the public market then refused to keep funding.

Lens 10 · Forensic Red Flags

Forensic-analyst lens, web-only (no ingested financials/filings).

Accounting-risk read (from the `` financial summaries):

• Revenue recognition: instrument-vs-consumable-vs-service split is the area to watch in a tools company (instrument revenue point-in-time; service/warranty deferred). No specific recognition concern surfaced; the revenue decline is the issue, not its recognition.
• Gross-margin jump (45.7%→59.3% Q1-2024→Q1-2025): large enough to warrant scrutiny — driven by mix (more consumables, fewer low-margin instruments) and cost actions per the company. Plausible and consistent with the strategy, but a 13.6pt one-year GM swing in a shrinking-revenue business is the kind of figure a forensic analyst confirms against the 10-K (not ingested here → flag).
• Cash vs. earnings: burn was real and improving ($20.8M→$7.2M operating-cash use Q1 YoY) — consistent with the narrowing operating loss, no obvious divergence. The concern is absolute runway (~1yr), not quality-of-earnings games.
• Goodwill / intangibles: Akoya carried acquisition goodwill from Canopy/Acuity; impairment risk was live (sub-scale, falling revenue). Post-close, the market's verdict materialized inside Quanterix: a $19.3M impairment of in-process R&D tied to a TERMINATED Akoya diagnostic-development agreement (quarter ended 31-Mar-2026). That write-off is the clearest forensic confirmation that a piece of what Akoya was selling (its clinical-diagnostic optionality) was worth materially less than carried.
• SBC: life-tools companies lean on stock comp; specifics n/a.

Regulatory findings (required sub-section). Per regulatory/regulatory-findings.md (generated 2026-06-30): Akoya has no CIK and zero SEC Litigation Releases / AAERs — "public and not required to file" per the script (note: Akoya did file under CIK 1711933 while listed; the research-layer record simply lacks it, and EDGAR enforcement returned 0 findings).

• Non-SEC (FTC/DOJ/FDA/etc.): web search surfaced no material enforcement actions, consent decrees, fines, or penalties against Akoya Biosciences.
• 10-K Item 3 (Legal Proceedings): the FY2024 10-K (CIK 1711933) was not ingested; no material litigation surfaced in the `` summaries.
• Verdict: No material regulatory or legal findings — verified via the regulatory-findings file (SEC LR/AAER = 0), web search (no hits), as of 2026-06-30. The only "enforcement-adjacent" event is the routine merger/delisting mechanics, not a regulatory action.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection

There is no AKYA EPS to project — the equity was extinguished on 8-Jul-2025 (converted to 0.1461 QTRX shares + $0.38 cash per AKYA share). Forecasting standalone Akoya FY2026-2028 EPS is meaningless. No forecast.ts create is logged (correct per --watchlist rules, and doubly correct because the security doesn't exist).

What can be framed is the forward path of the Akoya assets inside QTRX (where a tradeable view lives), as scenarios — every line /:

• Base: Combined QTRX 2025 revenue $130–135M (incl. ~2 quarters of Akoya); pro-forma full-year $165–170M. $85M annualized synergy target (raised from the original $40M), 94% of integration milestones done, cash-flow breakeven targeted H2-2026. If synergies land and revenue stabilizes, QTRX reaches breakeven and the Akoya install base becomes a cross-sell asset.
• Bull (for QTRX): the combined ~2,300-instrument base drives double-digit organic growth in 2026 as funding normalizes; the blood+tissue "integrated biomarker" story wins pharma/translational budget; breakeven on schedule.
• Bear (for QTRX): the Akoya cross-sell thesis under-delivers (different buyers, different budgets); the $19.3M IPR&D impairment is the first of more; synergy cuts hit revenue capacity; the academic-funding winter persists into 2026 and QTRX burns through its cash before breakeven. The upsizing of the synergy target $40M→$85M is itself a tell that the combined cost base was heavier (and/or revenue weaker) than first underwritten.

The one number that matters: does QTRX reach H2-2026 cash-flow breakeven before the combined cash runs out? That is the live, scoreable question — and it belongs in a QTRX dossier/forecast, not an AKYA one.

Lens 12 · Bull vs Bear

(Framed as: "was there ever a standalone Akoya bull case, and what does the wreckage teach?")

Bull case (the story that failed): spatial biology is the next layer of -omics; Akoya had the fastest high-plex single-cell platform on FFPE, a growing installed base throwing off recurring reagent revenue, a clear path from research → clinical diagnostics (the high-value end), and improving gross margins + shrinking losses showing operating discipline. In a normal funding environment, a sub-scale leader in a structurally-growing niche is an acquisition target at a premium — which, technically, it became.

Bear case (what actually happened — 2-3 permanent impairments):

1. Capital intensity met a funding winter. A business that sells $100k+ instruments to grant-funded labs cannot grow when grants are cut ~28% and indirect-cost caps slash institutional budgets. The instrument line — the engine — went into reverse.
2. Sub-scale vs. a giant. 10x Genomics (and Bruker, post-NanoString) can out-spend, out-distribute, and out-last Akoya, and 10x pushed directly into spatial proteomics. A ~$82M-revenue loss-maker cannot win a capital war.
3. No funding runway + no contractual revenue. ~1 year of cash and a soft, funding-gated consumable annuity = a balance sheet that forces a sale.

Pre-mortem (it's 18 months out and the thesis broke — what happened?): for the standalone name, it already broke — the stock went to $1.29 and the company was absorbed. For QTRX carrying these assets: the thesis breaks if cross-selling fails, the funding winter extends, and synergy cuts gut the commercial engine, pushing breakeven past the cash runway → dilutive raise or distress.

Were the multiples too high? At IPO ($20, ~$714M cap on ~$55M revenue ≈ ~13× sales ) — yes, wildly, a classic 2021 profitless-growth overvaluation. At delist (~0.8× sales) — no, that was distressed-fair.

Contrarian view (what the market refused to see): the market treated Akoya's 2021 IPO as a durable-growth compounder when it was actually a sub-scale capital-equipment vendor in a niche that depends on the single most macro-sensitive funding source there is (government science budgets). The contrarian-but-correct read all along was: spatial biology is a real scientific revolution that will mostly accrue to the best-capitalized platform (10x), not to every sub-scale tool-maker — and most of the standalone spatial names (NanoString → bankruptcy, Akoya → distressed sale, Vizgen → merger) have now proven it.

Lens 13 · Devil's Advocate (short-seller)

Dismantling any remaining bull case on the Akoya assets / QTRX:

• What structurally breaks the model: revenue is gated by third-party grant funding the company doesn't control, and the consumable annuity is not contracted — so a downturn hits both the instrument (new placements) AND the consumable (utilization) lines at once. There is no defensive revenue floor.
• Revenue concentration / shift: heavy academic + US exposure into the worst US academic-funding shock in decades (NIH new-grant awards −~$2.3B / ~28% in 9 months of 2025, 15% indirect-cost cap). If that concentration is the demand base, the demand base just got cut.
• Why the moat is weaker than bulls think: "fastest high-plex" is a spec lead, not a structural moat — 10x has more capital, a bigger installed base, broader multi-omic menu, and is invading spatial proteomics. Switching costs (panel re-validation) slow churn but don't stop a better-funded competitor from winning new placements, which is where the growth is.
• Most dangerous competitor bulls underestimate: 10x Genomics — not because Akoya's tech is worse on plex, but because 10x can afford to lose money longer and bundle spatial into a dominant single-cell franchise. Bruker (with NanoString's GeoMx/CosMx + a dedicated Spatial Division) is the second jaw of the vise.
• Worst capital-allocation move: arguably IPO-ing a capital-intensive tools business into public markets that then refused to fund its losses — and (for QTRX) acquiring a declining, cash-burning asset whose clinical-diagnostic optionality the parent then wrote off ($19.3M IPR&D impairment) and whose development agreement it terminated. That impairment is the short-seller's "I told you so."
• What must hold for QTRX's price: that $85M of synergy cuts land without crippling revenue, AND the academic-funding winter thaws, AND cross-selling blood↔tissue actually works — three things that must all go right, on a clock, with limited cash.
• −20-30% growth-disappointment scenario: combined organic revenue flat-to-down in 2026 (vs. the "double-digit growth" pitch) → breakeven slips past the cash runway → emergency raise/distress. Single scenario that permanently impairs: persistent NIH/academic funding cuts through 2026-2027 structurally shrink the addressable instrument market for everyone sub-scale; QTRX/Akoya, lacking 10x's balance sheet, cannot wait it out.

Lens 14 · Management Questions (ordered by information value)

(Directed at Quanterix management, since Akoya is now inside QTRX — these are the questions that would most change a forward view.)

1. What is the combined cash balance and quarterly burn today, and on the current plan, in which quarter do you reach self-funding cash-flow breakeven — and what is the cash cushion if it slips two quarters?
2. The synergy target was raised from $40M to $85M. How much of that extra $45M is revenue-capacity-reducing (cutting commercial/sales) vs. pure overhead, and what does it imply about the standalone businesses you bought/own?
3. You took a $19.3M IPR&D impairment and terminated an Akoya diagnostic-development agreement. Which Akoya clinical/diagnostic programs survive, and what does that say about the "research → diagnostics" thesis that justified the deal?
4. Of the combined ~2,300 installed instruments, what is the actual cross-sell attach to date (Simoa↔PhenoCycler) — in units and dollars — vs. the plan?
5. What is current consumable pull-through per instrument for the Akoya platforms, and how has utilization trended through the 2025 funding cuts?
6. What share of combined revenue is US academic/government, and what is your demand assumption for that cohort in 2026?
7. How is instrument booking activity trending in the most recent quarter vs. the comparable prior period — is the capital-equipment freeze thawing?
8. Where does 10x Genomics' push into spatial proteomics most directly threaten the Akoya franchise, and how do you defend new-placement share?
9. What is the gross-margin trajectory for the combined company, and how much of Akoya's 59% Q1-2025 margin survives integration?
10. What are the remaining integration milestones (you cited 94% done) and the costs/risks to finish them?
11. What is the organic revenue growth assumption embedded in the "double-digit 2026 growth" guidance, stripped of the merger's full-year-vs-partial-year optics?
12. What is your capital plan if breakeven slips — equity, debt, or asset sale — and at what trigger?
13. Which legacy products (Akoya or Simoa) are candidates for rationalization/discontinuation, and what revenue is at risk?
14. What clinical/regulatory milestones (LDT, IVD, partnerships) are required to move the combined platform into recurring diagnostic revenue, and on what timeline?
15. What is the single assumption in your plan that, if wrong, most threatens the company's independence/solvency?

---